drug development – mycolab.ai

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Special Issue: Marine-Derived Compounds Applied in Cardiovascular Disease

mycolabadmin

This collection of studies explores how compounds from ocean sources like seaweed, fish, shrimp, and microalgae can help protect heart health and prevent cardiovascular diseases. Researchers examined various marine ingredients and found they can reduce inflammation, lower cholesterol, reduce blood pressure, and prevent blood clots. The findings suggest that marine-derived products could become safer, more affordable alternatives or complements to current heart disease medications while supporting sustainable ocean resource use.

Bioactive Peptides and Other Immunomodulators of Mushroom Origin

mycolabadmin

Mushrooms contain special compounds called peptides and proteins that can boost your immune system and fight harmful bacteria. These mushroom-derived compounds show promise as natural alternatives to antibiotics, which are becoming less effective due to antibiotic resistance. Researchers are studying how these mushroom compounds could help treat difficult infections, wounds that won’t heal, and cancer, though more testing is needed before they can be used widely as medicines.

Ganoderma lucidum methanolic extract as a potent phytoconstituent: characterization, in-vitro antimicrobial and cytotoxic activity

mycolabadmin

Researchers tested a medicinal mushroom extract (Reishi/Ganoderma lucidum) to see if it could fight cancer and bacterial infections. The extract showed promising results, being particularly effective against blood cancer and breast cancer cells while being less toxic to normal healthy cells. It also killed bacteria better than some standard antibiotics, suggesting it could potentially be developed into a new type of medicine for treating cancer and infections.

Lentinan inhibits colorectal cancer stemness by binding CD133 and suppressing the CD133/p85/p-AKT signaling axis

mycolabadmin

Researchers discovered that lentinan, a natural compound from shiitake mushrooms, can specifically target and kill cancer stem cells in colorectal cancer by binding to a protein called CD133. This is significant because cancer stem cells are the reason why cancers come back even after treatment. By blocking a specific pathway these cells use to survive, lentinan may help prevent cancer recurrence and reduce the side effects associated with traditional chemotherapy.

A Novel, Non-Hallucinogenic Psychedelic for the Treatment of OCD and Tic Disorder

mycolabadmin

Researchers developed a new drug called HBL20017 based on psychedelic compounds that does not cause hallucinations. In animal tests, this drug significantly reduced obsessive behaviors and involuntary muscle twitches, suggesting it could treat conditions like obsessive-compulsive disorder and Tourette’s syndrome. A single dose showed beneficial effects that lasted up to 42 days, and the compound appeared safer than existing psychedelic treatments.

Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα

mycolabadmin

This study uses computer simulations to understand how psilocin (the active compound in magic mushrooms) and serotonin interact with a brain receptor called 5HT 2A R. The research shows that both molecules prefer to bind to a deeper part of the receptor rather than a shallower area, and that a protein called Gqα is essential for keeping the receptor in its active state. These findings could help scientists develop better medicines for depression and anxiety.

The development of psilocybin therapy for treatment-resistant depression: an update

mycolabadmin

Psilocybin, a compound found in certain mushrooms, is being studied as a potential treatment for severe depression that doesn’t respond to standard medications. In clinical trials, patients receiving psilocybin alongside psychological support showed significant improvement in depressive symptoms within days to weeks, with benefits lasting for months. Unlike daily antidepressant pills, psilocybin therapy involves one or more carefully supervised dosing sessions in a hospital setting with therapeutic support before and after. Larger studies are underway to confirm its effectiveness and safety before it could potentially become an approved treatment.

rFIP-GMI Suppresses IGF-1–Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β-Catenin Inhibition

mycolabadmin

Researchers found that a protein from a medicinal mushroom called Ganoderma microsporum can fight aggressive breast cancer by blocking a cellular pathway that helps cancer cells spread. The protein works by stopping the activation of key molecules (PI3K and Akt) that cancer cells use to invade surrounding tissues and migrate to other parts of the body. By blocking this pathway, the mushroom protein also prevents another molecule called β-catenin from entering the cell nucleus, where it would trigger genes that promote cancer growth and spread.

Advances in Fungal Infection Research: From Novel Diagnostics to Innovative Therapeutics

mycolabadmin

Fungal infections are becoming increasingly serious, especially for people with weakened immune systems, and some fungi are developing resistance to current medications. Researchers are developing faster diagnostic tests using molecular techniques and exploring new treatment approaches including repurposing existing drugs and developing vaccines. Monitoring and prevention programs in hospitals are essential to control the spread of these infections and improve patient outcomes.

Research Topic: drug development